

Form PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.  
2132.074APPLICATION NO.  
09/954,972

OIP (Rev. 2-88)

JAN 8 2002

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANTAPPLICANT  
JACKOWSKI et al.FILING DATE  
09/17/01GROUP  
1646

(Use several sheets if necessary)

## U.S. PATENT DOCUMENTS

EXAMINER'S INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BTN		Rossini et al., Animal models of human disease, Clin. Immunol. Immunopathol., (1995) 74, pp.2-9.
		Winer et al., Peptide dose, MHC affinity, and target self-antigen expression are critical for effective immunotherapy of nonobese diabetic mouse prediabetes, J. Immunol., (2000) 165, pp.4086-4094.
		Winer et al., Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; Nonimmunized nonobese diabetic mice can develop autoimmune encephalitis, J. Immunol., (2001) 166, pp.2831-2841.
		Winer et al., T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice., J. Immunol., (2001) 166, pp.4751-4756.
		Lipton et al., Autoimmunity and genetics contribute to the risk of insulin-dependent diabetes mellitus in families: Islet cell antibodies and HLA DQ heterodimers., Amer. J. Epidemiol., (1992) 136, 5, pp.503-512.
		Verge et al., Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes., Diabetes, 47, pp.1857-1866.
		Karges et al., Self and non-self antigen in diabetic autoimmunity: Molecules and mechanisms., Molec. Aspects Med., (1995) 16, pp.79-213.
		Donev, Ultrastructural evidence for the presence of a glial sheath investing the islets of langerhans in the pancreas of mammals., Cell and Tissue Research, (1984) 237, pp.343-348.
BTN		Takahashi et al., Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody., Clin. Chem., (1999) 45, 8, pp.1307-1311.
		Atkinson et al., The NOD mouse model of type I diabetes: As good as it gets?, Nat. Med., (1999) 5, 6, pp.601-604.

EXAMINER

DATE CONSIDERED

6-1-04

\* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/954,972
Filing Date	09/17/2001
First Named Inventor	George Jackowski
Art Unit	1641
Examiner Name	Bao Thuy Nguyen
Attorney Docket Number	2132.074

Sheet 1 of 3

Examiner Initials*	Cite No. <sup>1</sup>	U. S. PATENT DOCUMENTS		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Document Number	Publication Date MM-DD-YYYY		
BTN		US- 5,290,678	03/01/1994	G. Jackowski	<div>RECEIVED OCT 06 2003 TECH CENTER 1600/2900</div>
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

Examiner Initials*	Cite No. <sup>1</sup>	FOREIGN PATENT DOCUMENTS		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>2</sup>
		Foreign Patent Document	Publication Date MM-DD-YYYY			
BTN		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO00/26668	05/11/2000	The Regents of the	<div>✓</div>	
				Univ of Michigan		
		WO01/13934	03/01/2001	Virginia Mason		
J				Research Center		
		WO02/093174	11/21/2002	Syn.X Pharma, Inc.		

Examiner Signature	<i>B. Nguyen</i>	Date Considered	6/1/04
-----------------------	------------------	--------------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.





PTO/SB/088 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	09/954,972
Filing Date	09/17/2001
First Named Inventor	George Jackowski
Art Unit	1641
Examiner Name	Bao Thuy Nguyen
Attorney Docket Number	2132.074

Sheet 3 of 3

RECEIVED  
OCT 08 2003  
TECH CENTER 1600/2900**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
BTN		A. POLETAEV et al, "Serum Anti-S100b, anti-GFAP and anti-NGF autoantibodies of IgG Class in Healthy Persons and Patients with Mental and Neurological Disorders", Database Accession No. NLM10958173 XP002242994 Abstract and Autoimmunity, 32(1):33-38 (2000)	
		M. GORNY et al, "Anti-GFAP antibodies in the Cerebrospinal Fluid of Patients with Multiple Sclerosis and Other Neurologic Diseases", Database Accession No. NLM2132049 XP002242995 Abstract and Neurologia i Neurochirurgia Polska., 24(1-2):17-22 (January, 1990)	
BTN		K. ISHIDA et al, "Identification and Characterization of an Anti-Glial Fibrillary Acidic Protein Antibody with a Unique Specificity in a Demented Patient with an Autoimmune Disorder", J. Neurol. Sci., 151:41-48 (1997)	

Examiner Signature	<i>Bao Thuy Nguyen</i>	Date Considered	6/1/04
--------------------	------------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.